OncoMatch/Clinical Trials/NCT04707300
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
Is NCT04707300 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Human T Lymphoid Progenitor (HTLP) for hematologic malignancy.
Treatment: Human T Lymphoid Progenitor (HTLP) — This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: participation in another protocol in which drugs may influence immune reconstitution of bone marrow transplantation
Previous participation within one month before inclusion in another protocol in which drugs may influence immune reconstitution of bone marrow transplantation
Lab requirements
Kidney function
creatinine clearance <60ml/min [excluded]
Liver function
ALT/AST >10xULN, total bilirubin >2.5xULN [excluded]
Cardiac function
Left ventricular ejection fraction <50% [excluded]
Left ventricular ejection fraction <50%; Abnormal biochemistry results (ALT/AST>10xULN, total bilirubin>2.5xULN, creatinin clearance <60ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify